Regulation of AUF1 alternative splicing by hnRNPA1 and SRSF2 modulate the sensitivity of ovarian cancer cells to cisplatin

Author:

liu chuan1,Wang Jia-Mei2,Liu Ning3,Wei Xue-Jing2,Zhao Fu-Ying2,Li Chao2,Wang Hua-Qin2

Affiliation:

1. Shengjing Hospital of China Medical University;

2. China Medical University

3. Shengjing Hospital of China Medical University

Abstract

Abstract Ovarian cancer is one of the most prevalent gynecologic malignancies, with a poor prognosis due to its late-stage diagnosis, frequently presenting as highly advanced disease with concomitant drug resistance. Alternative splicing plays an important role in the evolution, development and disease of organisms. Tumor-specific alternative splicing events related to prognosis might be a great significance for tumor diagnosis and prediction and may even become effective targets for tumor therapy. AU-rich element RNA-binding protein 1 (AUF1) is a nucleic acid binding protein that is also known as heterogeneous ribonucleoprotein D (hnRNPD). Alternative splicing of the AUF1 precursor mRNA produces four different mRNA splicing variants, which encode four different molecular weights of protein isoform, p37, p40, p42 and p45 respectively. In this study, we demonstrated that different isoforms of AUF1 played a bidirectional role in ovarian cancer. In ovarian cancer, p37 isoform played a “cancer promoter” role, p42 and p45, especially p45 played a “cancer suppressor” role. The competitive binding of phosphorylated hnRNPA1 and O-GlcNAc modified SRSF2 on exon 2 and exon 7 of AUF1 regulated the alternative splicing of AUF1 and mediated the decrease of cisplatin responsiveness in ovarian cancer. This study provides a new target for exploring the drug resistance mechanism of ovarian cancer.

Publisher

Research Square Platform LLC

Reference35 articles.

1. Juarez-Mendez S, Zentella-Dehesa A, Villegas-Ruiz V, Perez-Gonzalez OA, Salcedo M, Lopez-Romero R, Roman-Basaure E, Lazos-Ochoa M, Montes de Oca-Fuentes VE, Vazquez-Ortiz G et al: Splice variants of zinc finger protein 695 mRNA associated to ovarian cancer. J Ovarian Res 2013, 6(1):61.

2. Treatment of recurrent epithelial ovarian cancer;Pignata S;Cancer,2019

3. Treatment of recurrent ovarian cancer;Pignata S;Ann Oncol,2017

4. Bookman MA, Okamoto A, Stuart G, Yanaihara N, Aoki D, Bacon M, Fujiwara K, Gonzalez-Martin A, Harter P, Kim JW et al: Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference. Ann Oncol 2017, 28(suppl_8):viii30-viii35.

5. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial;Pujade-Lauraine E;J Clin Oncol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3